Novartis AG Stock News

Novartis (NVS) posts results from a late-stage study on radioligand therapy at the 2021 ASCO.

Novartis AG (NYSE: NVS) has announced results from Phase 3 VISION study evaluating 177Lu-PSMA-617, a targeted radioligand therapy, plus best standard of care (SOC) in patients with progressive PSMA

Basel, June 3, 2021 — Novartis today announced that results of the Phase III VISION study evaluating 177Lu-PSMA-617, a targeted radioligand therapy, plus best standard of care (SOC) demonstrated sig

Novartis AG (NYSE: NVS) said that the Phase 3 JUNIPERA study met its primary endpoint, with Cosentyx (secukinumab) showing a significantly longer time to worsening of symptoms compared to placebo in

The FDA has approved Novartis AG's (NYSE: NVS) Cosentyx (secukinumab) to treat moderate to severe plaque psoriasis in pediatric patients six years and older and are candidates for systemic therapy

Novartis AG (NYSE: NVS) has announced that three Phase 3 studies evaluating Beovu (brolucizumab) in patients with retinal diseases will be terminated early after more frequent dosing intervals were

Kiplinger "insights for investors" online, first offered this list of 91 "Top Dividend Stocks From Around The World" July 13, 2020. Data updated 5/25/21 revealed 13 yields ripe for picking. These Inte

Novartis (NVS) initiates study for investigating its novel DARPin therapeutic candidate, ensovibep (MP0420), for the treatment of COVID-19, in collaboration with Molecular Partners.

Novartis AG (NYSE: NVS) along with Molecular Partners AG (OTC: MLLCF) is kicking off a Phase 2/3 EMPATHY study of DARPin therapeutic candidate, ensovibep (MP0420), to treat COVID-19. The program

Novartis AG (NVS) Presents at Cardiovascular Update Broker Conference Call - (Transcript)

The Supreme Court turned away a petition from Sandoz seeking to challenge two Amgen Inc (NASDAQ: AMGN) patents related to rheumatoid arthritis drug Enbrel, thus blocking Novartis AG's (NYSE: NVS

3 Big Drugmaker Stocks to Watch Out For Amid Pandemic Woes

The following three stocks may be of interest to dividend investors, as they are offering much higher dividend yields than the S&P 500 Index. The benchmark index's dividend yields 1.38% as of Friday,

The stock price of Novartis AG (NYSE: NVS) increased by 1.01% as it went from $85.24 to $86.10 pre-market. This is why it happened.

Novartis AG (NYSE: NVS) has reported that its Beovu (brolucizumab) drug met primary endpoints in Phase 3 KESTREL and KITE trials conducted in diabetic macular edema (DME) patients. According t